SCHEMBL319101

SCHEMBL319101

O=C(O)c1sc(-c2ccc(Oc3ccccc3)cc2)cc1N(CC(=O)N1CCOCC1)C(=O)c1ccc(Cl)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ HTT P42858 1/20 0.41
▸ FKBP1A P62942 1/20 0.41
▸ MMP2 P08253 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ CYP2E1 P05181 1/20 0.39
▸ HSD17B10 Q99714 2/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PTPRA P18433 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ EPHX2 P34913 1/20 0.36
▸ ABCC1 P33527 1/20 0.36
▸ LIPE Q05469 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318365 0.93 KDM4E (0.40) ALDH1A1KDM4EHTTFKBP1AMMP2
SCHEMBL319107 0.80 CYP2E1 (0.61) ALDH1A1KDM4EHTTFKBP1AMMP2
SCHEMBL319108 0.80 CYP2E1 (0.61) ALDH1A1KDM4EHTTFKBP1AMMP2
SCHEMBL325456 0.77 CYP2E1 (0.66) ALDH1A1KDM4ECYP2E1TDP1EPHX2
SCHEMBL2878555 0.75 CYP3A4 (0.38) —
SCHEMBL2158409 0.75 NPY1R (0.36) —
SCHEMBL319086 0.74 CYP2E1 (0.54) ALDH1A1KDM4EHTTMMP2MMP9
SCHEMBL319087 0.74 CYP2E1 (0.54) ALDH1A1KDM4EHTTMMP2MMP9
SCHEMBL2158053 0.74 CYP3A4 (0.43) —
SCHEMBL2158000 0.73 EPHX2 (0.36) EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 — — US disclosed
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 — — EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SLC10A1, ACE, CEL ALDH1A1 739/4885KDM4E 4146/4885HTT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback